Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | CTSS | P25774 | 9/20 | 0.50 |
| ▸ | CTSK | P43235 | 9/20 | 0.50 |
| ▸ | CTSL | P07711 | 1/20 | 0.48 |
| ▸ | CTSB | P07858 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | GLS | O94925 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ECE1 | P42892 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8536884 | 1.00 | KMT2A (0.57) | KMT2ACTSSCTSKCTSLCTSB | |
| SCHEMBL10760962 | 1.00 | KMT2A (0.57) | KMT2ACTSSCTSKCTSLCTSB | |
| SCHEMBL31506338 | 0.94 | KMT2A (0.52) | KMT2ACTSSCTSKCTSLCTSB | |
| SCHEMBL29918018 | 0.88 | KMT2A (0.55) | KMT2ACTSSCTSKCTSLCTSB | |
| SCHEMBL11901619 | 0.87 | KMT2A (0.53) | KMT2ACTSSCTSKCTSLCTSB | |
| SCHEMBL6234092 | 0.87 | KMT2A (0.53) | KMT2ACTSSCTSKCTSLCTSB | |
| SCHEMBL4388913 | 0.87 | KMT2A (0.53) | KMT2ACTSSCTSKCTSLCTSB | |
| SCHEMBL10841914 | 0.87 | KMT2A (0.53) | KMT2ACTSSCTSKCTSLCTSB | |
| SCHEMBL28827213 | 0.87 | KMT2A (0.53) | KMT2ACTSSCTSKCTSLCTSB | |
| SCHEMBL26419810 | 0.87 | KMT2A (0.53) | KMT2ACTSSCTSKCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260091024-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BIOHAVEN THERAPEUTICS LTD (US) | 2026-04-02 | — | — | US | disclosed |
| US-20260041673-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BIOHAVEN THERAPEUTICS LTD (US) | 2026-02-12 | — | — | US | disclosed |
| US-12472165-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2025-11-18 | — | — | US | disclosed |
| US-20250332148-A1 | RILUZOLE PRODRUGS AND THEIR USE | BIOHAVEN THERAPEUTICS LTD (US) | 2025-10-30 | — | — | US | disclosed |
| US-20250304563-A1 | ACTIVATORS OF EFFECTOR T CELLS | ORUM THERAPEUTICS, INC. (KR) | 2025-10-02 | — | — | US | disclosed |
| US-12295942-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2025-05-13 | — | — | US | disclosed |
| US-12213965-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2025-02-04 | — | — | US | disclosed |
| EP-4490152-A1 | ACTIVATORS OF EFFECTOR T CELLS | Orum Therapeutics Inc. (KR) | 2025-01-15 | — | — | EP | disclosed |
| US-12005046-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (US) | 2024-06-11 | — | — | US | disclosed |
| US-12005047-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (US) | 2024-06-11 | — | — | US | disclosed |
| CN-107567438-A | Riluzole prodrug and application thereof | 拜尔哈文制药股份有限公司 | 2018-01-09 | — | — | CN | disclosed |
| US-9169295-B2 | Macrocycles and macrocycle stabilized peptides | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-10-27 | — | — | US | disclosed |
| EP-2627662-B1 | METHODS FOR PREPARING MACROCYCLES AND MACROCYCLE STABILIZED PEPTIDES | BRISTOL MYERS SQUIBB CO (US) | 2015-09-16 | — | — | EP | disclosed |
| CN-101928326-B | Substitution five-heterocyclic alkyl aminoacyl compound and application thereof | INST PHARM & TOXICOLOGY AMMS | 2015-07-08 | — | — | CN | disclosed |
| US-20130281657-A1 | MACROCYCLES AND MACROCYCLE STABILIZED PEPTIDES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-10-24 | — | — | US | disclosed |
| CN-101928326-A | Substitution five-heterocyclic alkyl aminoacyl compound and application thereof | INST PHARM & TOXICOLOGY AMMS | 2010-12-29 | — | — | CN | disclosed |
| US-5750555-A | NERVOUS SYSTEM DISORDERS; SKIN DISORDERS; IMMUNOLOGY | GOEDECKE AKTIENGESELLSCHAFT (DE) | 1998-05-12 | — | — | US | disclosed |
| EP-0674632-A1 | AMINOACID DERIVATIVES OF HETEROCYCLES AS PROTEIN KINASE C INHIBITORS | GÖDECKE AKTIENGESELLSCHAFT (DE) | 1995-10-04 | — | — | EP | disclosed |
| WO-1994014798-A1 | AMINOACID DERIVATIVES OF HETEROCYCLES AS PROTEIN KINASE C INHIBITORS | Gödecke Aktiengesellschaft (DE) | 1994-07-07 | — | — | WO | disclosed |
| US-3991041-A | GROWTH HORMONE RELEASE INHIBITOR | AMERICAN HOME PRODUCTS CORPORATION (US) | 1976-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260091024-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | IL6ST, GFRA3, GFRA1 | KMT2A 3288/4885CTSS 1265/4885CTSK 1499/4885 |
| US-12005046-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | KMT2A 2213/4885CTSS 653/4885CTSK 586/4885 |
| US-20250304563-A1 | ACTIVATORS OF EFFECTOR T CELLS | CBLB, CBL, CBLC | KMT2A 1486/4885CTSS 874/4885CTSK 715/4885 |
| US-12005047-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | KMT2A 2213/4885CTSS 653/4885CTSK 586/4885 |
| US-20260041673-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | GFRA3, IL6ST, GFRA1 | KMT2A 3363/4885CTSS 1454/4885CTSK 1659/4885 |
| US-12472165-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | KMT2A 2213/4885CTSS 653/4885CTSK 586/4885 |
| US-12295942-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | KMT2A 2213/4885CTSS 653/4885CTSK 586/4885 |
| US-20130281657-A1 | MACROCYCLES AND MACROCYCLE STABILIZED PEPTIDES | PTMS, VIP, MTPN | KMT2A 3949/4885CTSS 176/4885CTSK 492/4885 |
| US-20250332148-A1 | RILUZOLE PRODRUGS AND THEIR USE | APEH, ALDH1A2, UGT1A9 | KMT2A 2213/4885CTSS 653/4885CTSK 586/4885 |
| US-12213965-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | KMT2A 2213/4885CTSS 653/4885CTSK 586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.